WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
11 November 2010
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound
03 November 2010
Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance
27 October 2010
Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc.
10 September 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
08 September 2010
Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation
26 August 2010
Ipilimumab Receives FDA Priority Review Designation
19 August 2010
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
23 July 2010
ONGLYZA (saxagliptin) with Metformin as Initial Combination Therapy
28 June 2010
Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL
15 June 2010
AVERROES Study Closes Early Due to Clear Evidence of Efficacy
11 June 2010
Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter
03 May 2010
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus
10 March 2010
Bristol-Myers Squibb and Allergan Enter Global Agreement
05 March 2010
FDA Advisory Committee Recommends Approval of Belatacept
03 March 2010
Bristol-Myers Squibb supporting efforts to help survivors
21 January 2010
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
08 December 2009
"Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
01 December 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement
11 November 2009
Bristol-Myers Squibb Achieves Strong Sales
23 October 2009
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Research & Development
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Engineered bacteria find tumors, then alert the authorities
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
Bristol-Myers Squibb